

REMARKS

interview summary
OK, CUS, 10/24/07

Applicants thank Examiner Smith for her time and helpful comments during a telephonic interview with the undersigned representative on April 4, 2006. The substance of the interview related to the rejections of the claims under 35 U.S.C. § 112, first paragraph (written description) and under 35 U.S.C. § 112, second paragraph. Possible claim amendments and arguments were discussed, but no agreement was reached.

Reconsideration of the present Application in view of the Amendment and Request for Continued Examination enclosed herewith and the following remarks is respectfully requested. Claims 58, 71, 73, and 74 are currently pending. Applicants have amended claims 58 and 71 and added new claims 75 and 76 to point out with greater particularity and distinctly claim certain embodiments of Applicants' invention. Support for the amended and new claims may be found throughout the specification, for example, at page 13, lines 1-8; page 29, line 24 through page 30, line 1; page 33, lines 1-8; page 31, lines 20-25; and at page 33, lines 10-13; page 35, lines 13-14. Table 4 (page 71) of the specification has been amended to point out with greater particularity that the first column lists cell surface marker antigen specificity of immunoglobulin molecules that were included in an exemplary array (*see* page 63, lines 21-24; *see also* page 62, lines 3-11; page 17, line 30 through page 18, line 7 (describing Figure 7, which is the graphic representation of the summary in Table 4)). No new matter has been added to the application. Upon entry of the amendments submitted herewith, claims 58, 71, and 73-76 will be pending.

Rejections Under 35 U.S.C. § 112, First Paragraph (Written Description)

Claims 58, 71, 73, and 74 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to comply with the written description requirement. The Action asserts that the claims contain new subject matter that was not described in the specification. Specifically, the Action asserts that the specification does not adequately support the feature "antigen-binding derivatives."